Literature DB >> 26617858

Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.

Lei-Yi Zhang1, Jiang-Sheng Huang1, Zhi-Min Pi1, Mei-Ying Yu1.   

Abstract

To investigate the inhibition effect of polyethylene glycol interferon α-2b and imatinib alone or combination on imatinib-resistant GIST cell lines, and to explore the possible mechanism. Imatinib resistant GIST cell lines (GIST-R) were exposured to either Peg-IFNα-2b or imatinib alone or combination. The proliferative inhibition rates and the combination index (CI) values of GIST-R cells were detected by MTT assay. The apoptotic rates of GIST-R cells were detected by flow cytometry. The expression levels of phospho-mammalian target of rapamycin (p-mTOR), and Bcl-2 of GIST-R cells were analyzed by Western blot. GIST-R cells presents remarkable resistance to imatinib, and the resistance index (RI) were (P<0.05). And The proliferative inhibition rate and the apoptotic rate of GIST-R cells in combination of Peg-IFNα2b and Imatinib group were higher than those in Peg-IFNα-2b or imatinib alone group (P<0.05). The CI value of Peg-IFNα-2b and imatinib was less than each alone, which had a synergistic effect (CI=0.63). As compared with the control (GIST-R cells without any treatment), the expression levels of p-mTOR and Bcl-2 proteins of GIST-R cells in combination of Peg-IFNα-2b and imatinib group were decreased (P<0.01). The combination of Peg-IFNα-2b and imatinib generats a synergistic effect in GIST-R cells, and reversal of drug resistance. This effect may be related with apoptosis and down-regulation of the expression of p-mTOR.

Entities:  

Keywords:  GIST; combination; drug resistance; imatinib; polyethylene glycol interferonα-2b; sensibilization

Mesh:

Substances:

Year:  2015        PMID: 26617858      PMCID: PMC4637674     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  19 in total

Review 1.  BAY 43-9006: preclinical data.

Authors:  Scott Wilhelm; Du-Shieng Chien
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

2.  Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala.

Authors:  Sean R McLean; Mali Gana-Weisz; Basil Hartzoulakis; Richard Frow; Jeremy Whelan; David Selwood; Chris Boshoff
Journal:  Mol Cancer Ther       Date:  2005-12       Impact factor: 6.261

3.  Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

Authors:  Cédric Ménard; Jean-Yves Blay; Christophe Borg; Stefan Michiels; François Ghiringhelli; Caroline Robert; Céline Nonn; Nathalie Chaput; Julien Taïeb; Nicolas F Delahaye; Caroline Flament; Jean-François Emile; Axel Le Cesne; Laurence Zitvogel
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 4.  Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.

Authors:  E Jonasch; F G Haluska
Journal:  Oncologist       Date:  2001

Review 5.  Phosphorylation of Bcl2 and regulation of apoptosis.

Authors:  P P Ruvolo; X Deng; W S May
Journal:  Leukemia       Date:  2001-04       Impact factor: 11.528

Review 6.  Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.

Authors:  Ronald M Bukowski; Craig Tendler; David Cutler; Esther Rose; Mark M Laughlin; Paul Statkevich
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

7.  Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.

Authors:  Christophe Borg; Magali Terme; Julien Taïeb; Cédric Ménard; Caroline Flament; Caroline Robert; Koji Maruyama; Hiro Wakasugi; Eric Angevin; Kris Thielemans; Axel Le Cesne; Véronique Chung-Scott; Vladimir Lazar; Isabelle Tchou; Florent Crépineau; François Lemoine; Jacky Bernard; Jonhantan A Fletcher; Ali Turhan; Jean-Yves Blay; Alain Spatz; Jean-François Emile; Michael C Heinrich; Salah Mécheri; Thomas Tursz; Laurence Zitvogel
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 8.  Novel approaches to imatinib- and sunitinib-resistant GIST.

Authors:  Peter Reichardt
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

9.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

10.  Exploiting antitumor immunity to overcome relapse and improve remission duration.

Authors:  Lei L Chen; Xinjian Chen; Haesun Choi; Hongxun Sang; Leo C Chen; Hongbo Zhang; Launce Gouw; Robert H Andtbacka; Benjamin K Chan; Christopher K Rodesch; Arnie Jimenez; Pedro Cano; Kimberly A Jones; Caroline O Oyedeji; Tom Martins; Harry R Hill; Jonathan Schumacher; Carlynn Willmore; Courtney L Scaife; John H Ward; Kathryn Morton; R Lor Randall; Alexander J Lazar; Shreyaskumar Patel; Jonathan C Trent; Marsha L Frazier; Patrick Lin; Peter Jensen; Robert S Benjamin
Journal:  Cancer Immunol Immunother       Date:  2011-12-24       Impact factor: 6.968

View more
  1 in total

Review 1.  Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis.

Authors:  Gloria Ravegnini; Giulia Sammarini; Margherita Nannini; Maria A Pantaleo; Guido Biasco; Patrizia Hrelia; Sabrina Angelini
Journal:  Autophagy       Date:  2017-01-05       Impact factor: 16.016

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.